
United Therapeutics (UTHR) Stock Forecast & Price Target
United Therapeutics (UTHR) Analyst Ratings
Bulls say
United Therapeutics is expanding its indications, innovating in drug delivery, and has a strong and experienced management team, leading to positive outlook for future growth. Though there are risks such as accelerated generic erosion of market share and increased competition, the company remains resilient with its positive TETON-1 and TETON-2 data, robust TETON-2 results in IPF, and a strong pipeline with multiple upcoming catalysts. This, combined with its strong business model and disciplined cost management, gives confidence in the company's potential for success and a bullish outlook.
Bears say
United Therapeutics is facing several challenges going forward including the need for more proof in the no-background-therapy subgroup to support monotherapy use, unclear positioning of nebulized Tyvaso compared to its other formulations, and low projected earnings growth compared to the industry average. These factors, along with a composite valuation methodology that yields a $600 PT, contribute to a negative outlook on UTHR's stock.
This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares